I totally agree that it would be a tremendous hassle and risk to build a whole distribution channel by ourselves.
But can you clarify what you mean by

Quote:

---

I would personally prefer we get to P3 and turn over all products to the professional marketers to take it from there

---

? Are you talking about a standard licensing deal?

As far as I see it here are the two options mentioned by Mo and a third option open for discussion:

1) Standard license deal
- License B-OM now to big pharma
- Phase 3 costs are paid by BP
- Marketing and distribution done by BP
- Ipix get upfront payments, milestone payments and a 15% cut of sales

2) "Going it alone" strategy
- Phase 3 costs paid by Ipix (from IBD upfront payment). Risk until NDA from FDA 100% Ipix.
- Marketing and distribution done by Ipix
- Ipix get NO upfront payments, NO milestone payments, BUT keeps 100% cut of sales

3) Mix of both
- Phase 3 costs paid by Ipix (from IBD upfront payment). Risk until NDA from FDA 100% Ipix.
- Marketing and distribution done by BP
- Ipix get NO upfront payments, NO milestone payments, BUT Ipix keeps X% cut of sales

So basically in option #3 we carry costs and risk all the way until we have a marketable product with a NDA granted by the FDA. In this case I assume the should get a higher sales cut, right? But how high? Maybe 50/50% cut of sales?

As far as I know Ipix always preferred option #1, right? Option #2 is the most hassle, biggest risk but also biggest return by far. I was wondering what the real-life chance of option #3 is and how much more of possible ROI is to expect in this case.

Correct me if I'm wrong or misunderstood any of our options.